Pharmacokinetic interaction between verapamil and everolimus in healthy subjects

This publication has 8 references indexed in Scilit:

• Everolimus Therapeutic Concentration Range Defined from a Prospective Trial with Reduced-Exposure Cyclosporine in De Novo Kidney Transplantation
  Therapeutic Drug Monitoring, 2004
• Everolimus: A proliferation signal inhibitor targeting primary causes of allograft dysfunction
  Drugs of Today, 2004
• The Conduct of In Vitro and In Vivo Drug-Drug Interaction Studies: A PhRMA Perspective
  The Journal of Clinical Pharmacology, 2003
• Role of P-Glycoprotein in Pharmacokinetics
  Clinical Pharmacokinetics, 2003
• Pharmacokinetic and Pharmacodynamic Assessments of HMG‐CoA Reductase Inhibitors When Coadministered with Everolimus
  The Journal of Clinical Pharmacology, 2002
• High‐throughput semi‐automated 96‐well liquid/liquid extraction and liquid chromatography/mass spectrometric analysis of everolimus (RAD 001) and cyclosporin a (CsA) in whole blood
  Rapid Communications in Mass Spectrometry, 2001
• Dose of midazolam should be reduced during diltiazem and verapamil treatments.
  British Journal of Clinical Pharmacology, 1994
• Inter- and intra-subject variation in the first-pass elimination of highly cleared drugs during chronic dosing
  European Journal of Clinical Pharmacology, 1984